Pipeline new from Galera, Jazz, Merrimack, and DBV Technologies

March 5, 2018

Company Drug/Device Medical Condition Status
MabVax Therapeutics Holdings, Inc. MVT-1075 Pancreatic, colon and lung cancer Phase I
BioAtla, LLC BA3011 Advanced solid tumors including non-small cell lung cancer (NSCLC) castration resistant prostate cancer and pancreatic cancer Phase I/II trials initiated
Galera Therapeutics, LLC GC4419 Locally advanced pancreatic cancer (LAPC) Phase I/II trials initiated
Jazz Pharmaceuticals Defitelio (defibrotide sodium) Acute Graft-versus-Host-Disease (aGvHD) in adult and pediatric patients after allogenic hematopoietic stem cell transplant (HSCT) Phase II trials initiated enrolling 150 subjects in the U.S., Canada and European Union
DBV Technologies Viaskin Milk IgE-medicated cow’s milk protein allergy Phase II trials initiated enrolling 198 subjects
Merrimack Pharmaceuticals, Inc. MM-121 (seribantumab) Heregulin-positive, hormone rececptor-positive and HER2-negative post-menopausal metastic breast cancer Phase II trials initiated
ARCA biopharma Gencaro (bucindolol hydrochloride) Atrial fibrillation Phase IIb trials initiated enrolling 267 subjects from the U.S., Canada and Europe
Nuvelution Pharma, Inc. AUSTEDO Tourette syndrome in pediatric patients Phase II/III trials initiated